Question

PR525 is a compound with potential activity in cardiovascular disease. The compound cannot be made into an intravenous dosage form because of stability issues. Investigators are conducting a phase I study administering two dosage forms- one oral tablet and the other an oral suspension- in a crossover study comparing the two dosage forms. Which pharmacokinetic parameter will be obtained from the conclusion of this study?

Group of answer choices

Therapeutic index

Absolute bioavailability

Relative bioavailability

Absolute bioequivalence

Relative bioequivalence

Answer 1

Relative bioavailability of PR525 will be determined. The bioavailability of PR525 in systemic circulation by oral tablet and oral suspension is calculated to check which dosage form having more or less sytemic bioavailability compare to other dosage form. if one of the dosage form is given by intravenous route then it will be considered as absolute bioavailability. Generally Bioeuivalence  is calculated on the basis of bioavailability of the drug. So in the conclusion of this study, the Relative bioavailability of PR525 is determined for oral tablet and an oral suspension dosage forms.